You searched for Cancer - Page 25 of 215

Investment Gap finance savings currency train bridge

News and Trends 23 Feb 2021

European Cancer Deals Increasingly Focus on Natural Killer Cells

Natural killer cells are becoming a hot topic in the booming cancer cell therapy scene, with the field’s latest big deal being a €640M licensing agreement between the French biotech Cellectis and US company Cytovia. T-cell immunotherapies like CAR T-cell therapy have revolutionized cancer treatment in recent times. However, they have a significant disadvantage. The […]

February 23, 2021 - 6 minutesmins - By Kostas Vavitsas

News and Trends 16 Feb 2021

Cancer Research UK Cuts Two Biotech Collaborations Amid Pandemic Squeeze

The major research funder CRUK and two of the biotech companies it works with have decided to cut development ties as the financial impact of the coronavirus disease pandemic continues to bite. Cancer Research UK (CRUK) is a prolific research charity, running a multitude of collaborations with academics and biotech companies around the world. However, […]

February 16, 2021 - 4 minutesmins - By Anita Chakraverty

News and Trends 16 Nov 2020

Innate Immunity in Cancer Gains Recognition with Affimed’s €1.8B Deal

Last week’s €1.75B deal between the German biotech Affimed and Swiss giant Roivant backs up an emerging trend of harnessing our innate immune system to treat cancer. According to the deal’s terms, Affimed will receive €51M upfront to license to Roivant a preclinical-stage antibody drug for several undisclosed types of cancer. Roivant will handle the […]

November 16, 2020 - 3 minutesmins - By Jonathan Smith

Interview 28 Oct 2020

Do Natural Killer Cells Hold the Key to Treating Blood Cancers?

Novel immunotherapies, like T cell therapy, may have shown recent successes but they also come with a number of setbacks, such as long timelines and serious adverse reactions. As CEO of the Dutch biotech Kiadis Pharma, Arthur Lahr has been leading the development of a technology that could overcome these limitations by using natural killer […]

October 28, 2020 - 7 minutesmins - By Larissa Warneck-Silvestrin

News and Trends 11 Aug 2020

How European Startups Have Advanced Cancer T-Cell Therapy in 2020

With the help of a huge €66M Series A round last week, the German startup T-knife is developing cancer T-cell immunotherapies with the help of genetically modified mice. However, this is just one of several cancer T-cell therapy startups making advances this year, with other innovations including off-the-shelf treatments and a potential universal cancer therapy. […]

August 11, 2020 - 8 minutesmins - By Kostas Vavitsas

News and Trends 24 Jul 2020

Swiss Company Raises €23M to Smash Cancer with Bacteria

Basel-based T3 Pharmaceuticals has closed its third financing round, worth over €23.3M (CHF 25M), to develop a bacterial cancer therapy. Since T3 Pharma was spun off from the University of Basel in 2015, the firm has raised €37M (CHF 40M). The fundraiser included investors such as Boehringer Ingelheim Venture Fund, Reference Capital, and Wille Finance. […]

July 24, 2020 - 2 minutesmins - By Antara Mazumdar

News and Trends 17 Jul 2020

Two UK Startups Raise Seed Funding to Revolutionize Cancer Treatment

Unfazed by the financial turmoil caused by the Covid-19 pandemic, the Edinburgh-based firm Macomics and University of Cambridge spinout Spirea have each closed seed rounds this week to finance the development of novel cancer immunotherapies and more precise forms of chemotherapy. Macomics bagged €3.5M (£3.2M) in seed funding from the transatlantic VC firm Epidarex Capital […]

July 17, 2020 - 3 minutesmins - By Kostas Vavitsas

pharmamar jazz pharmaceuticals lung cancer

News and Trends 19 Jun 2020

Cancer Drug Inspired by Sea Animal Gets FDA Green Light

The Spanish company PharmaMar’s stock price has shot up by 30% as its cancer drug lurbinectedin was given accelerated approval for the second-line treatment of metastatic small cell lung cancer in the US this week. Lurbinectedin will be marketed under the brand name Zepzelca and will be made commercially available in the US in early […]

June 19, 2020 - 3 minutesmins - By Manuela Callari

tumor cancer immunotherapy alderaan biotech

News and Trends 17 Jun 2020

€30M Series A to Fund Spanish Biotech’s Anti-Metastasis Cancer Drug

A Series A round closed by Barcelona-based startup Ona Therapeutics will finance the preclinical development of a drug that prevents cancer from spreading in the body by targeting the metabolism of cancer cells. The round was supported by returning investor Asabys Partners, as well as new European investors including Alta Life Sciences, Bpifrance, Fund+, and […]

June 17, 2020 - 2 minutesmins - By Victor Kotsev

News and Trends 8 Jun 2020

UK Startup Launches with €10M to Detect Epigenetic Signs of Cancer in Blood

A seed round of €10.1M will fund the launch of the University of Oxford spinout Base Genomics, which aims to improve cancer detection by measuring epigenetic changes to tumor DNA circulating in the blood. The company’s oversubscribed seed funding round was led by Oxford Sciences Innovation, a local early-stage investment firm linked to the University […]

June 8, 2020 - 3 minutesmins - By David Kirk

News and Trends 28 May 2020

French Startup Secures €2.3M to Advance Cancer RNA Immunotherapy

Lyon-based biopharmaceutical company Tollys has closed a Series A funding round of €2.3M to bring its lead RNA immunotherapy candidate to clinical trials in people with bladder cancer. The round was closed on the basis of the company reaching preclinical proof-of-concept for the drug. It brings the total amount raised by Tollys to €6.4M since […]

May 28, 2020 - 2 minutesmins - By Laura Cowen

genmab janssen blood cancer multiple myeloma

News and Trends 14 May 2020

Oncopeptides’ Share Issue Bags €133M to Take Cancer Drug to Market

Swedish biotech Oncopeptides has raised €133M (SEK 1.4B) by issuing new company shares, surpassing expectations and driving the launch of its targeted chemotherapy drug in the US. In what could be one of European biotech’s largest equity boosts this year, the company exceeded initial plans to raise €111M (SEK 1.2M) through Nasdaq Stockholm following a […]

May 14, 2020 - 3 minutesmins - By Anita Chakraverty

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us